(NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today the appointment of Stephen J. McAndrew, Ph.D., as Chief Business ...

PRINCETON, N.J., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company ...

Sonnet BioTherapeutics (SONN) announced the appointment of Stephen McAndrew, Ph.D., as Chief Business Officer, effective February 17, 2025. During the course of his tenure at Sonnet, Dr.

Detailed price information for Sonnet Biotherapeutics Holdings Inc (SONN-Q) from The Globe and Mail including charting and trades.

has announced the appointment of Stephen J. McAndrew, Ph.D., as its Chief Business Officer, starting February 17, 2025. According to InvestingPro data, the company faces significant challenges ...